Literature DB >> 1720902

Vasoactive intestinal polypeptide-, neurotensin-, substance P-, gastrin-releasing peptide-, calcitonin-, calcitonin gene related peptide-, and somatostatin-like immunoreactivities in human parathyroid glands.

C J Weber1, T M O'Dorisio, B Howe, V D'Agati, L Ward, J Russell, C R Feind.   

Abstract

We have found vasoactive intestinal polypeptide (VIP)-, neurotensin-, substance P-, gastrin-releasing peptide-, calcitonin-, calcitonin gene related peptide (CGRP-2)-, and somatostatin-like immunoreactivities in extracts of sporadic human parathyroid adenomas (n = 18). The content of CGRP-2, substance P, and somatostatin in adenomas correlated directly with that of parathyroid hormone. In addition, concentrations of VIP versus substance P and somatostatin versus CGRP-2 in adenomas were directly correlated. Neuropeptide content of parathyroid hyperplasias differed from that of adenomas. VIP was detected in only one of seven parathyroid hyperplasias, and neurotensin was undetectable (0/7), whereas substance P was present in six of seven cases and GRP in five of seven hyperplasias. In hyperplasias, content of substance P correlated directly with that of gastrin-releasing peptide. Peroxidase immunohistochemistry localized VIP-like immunoreactivity to 20% to 50% of both chief and oxyphilic cells and rare clear cells and capillary endothelium in 11 of 12 adenomas studied. Focal staining was present in glandular epithelium of the rim of adjacent normal parathyroid tissue and in two of three normal parathyroid glands removed with thyroid goiters. This staining was both cytoplasmic and apical membrane. By contrast, in adenomas, neurotensin- and substance P-like positivities were confined to scattered (5% to 10%) oxyphilic cells. Cytoplasmic positivity for parathyroid hormone, noted in 30% to 70% of cells in serial sections, confirmed that these tissues were indeed parathyroid glands.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720902

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  3 in total

1.  A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies.

Authors:  G Schwartsmann; L P DiLeone; M Horowitz; D Schunemann; A Cancella; A S Pereira; M Richter; F Souza; A Brondani da Rocha; F H Souza; P Pohlmann; G De Nucci
Journal:  Invest New Drugs       Date:  2006-09       Impact factor: 3.850

2.  Relationships of Na+ and K+ concentrations to GRP, CGRP, and calcitonin immunoreactivities and Na+,K(+)-ATPase (NKA) inhibitory activity in human breast cyst fluid.

Authors:  C J Weber; D Kim; M Costanzo; J Morris; B Howe; L Ward; V D'Agati; T McDonald; T M O'Dorisio; V P Butler
Journal:  Ann Surg Oncol       Date:  1994-07       Impact factor: 5.344

3.  Octreotide uptake in parathyroid adenoma.

Authors:  Seyhan Karaçavuş; Mustafa Kula; Züleyha Cihan Karaca; Kürşad Unlühızarcı; Ahmet Tutuş; Fahri Bayram; Ganime Coban
Journal:  Mol Imaging Radionucl Ther       Date:  2012-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.